Fresh analysis indicates that people who stop using new GLP-1 drugs like Wegovy and Mounjaro can put back on lost weight far faster than those who end conventional diet and exercise regimens.
Published data in a leading health publication points out that while overweight people often shed substantial amounts of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month after stopping.
"Users buying such medications should be aware of the risk of quick rebound weight gain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.
That rate of regain implies a reversion to original weight within about 18 months.
Weighing Treatments
The analysis, which reviewed 37 of trials involving thousands of participants, compared the effects of these new drugs with other pills.
The team point out that individuals who lose weight through dieting generally have a slower weight regain—perhaps 0.1 kg a month—post-intervention.
Explaining the Quick Rebound
Nutrition scientists believe the way of the jabs explains the heightened weight return.
These medications imitate a natural hormone called glucagon-like peptide-1, which controls hunger.
"Artificially providing the hormone levels several times higher than normal could lead to the system to generate a reduced amount of its own natural hormone, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this hormone supplement means appetite is no longer kept in check, making overeating much more probable."
An Ongoing Condition?
Medical guidelines advise the jabs for people with obesity-related health risks, accompanied by recommended diet and exercise modifications.
Many experts say that, given the likelihood of weight regain, the therapy is often life-long.
This perspective is reinforced by pharmaceutical companies, who note that the results "underscore the chronic nature of excess weight," similar to managing conditions like diabetes.
Patient Accounts
Individuals who have discontinued the jabs explain a sudden return of cravings.
"It was like a trigger flipping and I was suddenly ravenous," described a patient.
The struggle is exacerbated if individuals have not established sustainable lifestyle or habit modifications during therapy.
Significant Use
Survey data indicate that a significant number of people in the UK have tried these injections in the last 12 months, with desire being substantial.
- Adoption is more common among women than men.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Finally, clinicians caution that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent cure and lasting health benefits hinges on combined lifestyle management.
